Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of a recombinant quadrivalent HPV (16/18/52/58) VLP vaccine in adult women
CTR20190482Phase 2Completed
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Mar 2019
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant quadrivalent human papillomavirus (types 16/18/52/58) virus-like particle vaccine in Cervical Cancer (CC), cervical intraepithelial neoplasia (CIN), cervical adenocarcinoma in situ (AIS), human papillomavirus infection, anogenital warts, sponsored by Shanghai Institute of Biological Products. Started Mar 2019; status: completed.
02
Drugs
recombinant quadrivalent human papillomavirus (types 16/18/52/58) virus-like particle vaccine
03
Conditions
Cervical Cancer (CC)cervical intraepithelial neoplasia (CIN)cervical adenocarcinoma in situ (AIS)human papillomavirus infectionanogenital warts
Beyond the preview
Go deeper on CTR20190482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190482.